Bimeda US recently announced the launch of Gamrozyne™, the first and only bioequivalent to Zactran® (Boehringer-Ingelheim®). This milestone expands Bimeda’s robust antibiotic portfolio and offers veterinarians and producers an additional option for managing bovine respiratory disease (BRD).
Gamrozyne is a fast-acting injectable macrolide antibiotic labeled for treatment of BRD in beef and non-lactating dairy cattle. Gamithromycin has been proven to reach the target lung tissue within 30 minutes and delivers 10 days of treatment with a single subcutaneous injection. Gamrozyne is available in 250 mL and 500 mL presentations, with a dosage of 2 mL per 110 lb. administered in the neck.
Gamrozyne is a prescription-only medication and is not for use in female dairy cattle 20 months of age and older, or in calves intended for veal production. This product has a 35-day withdrawal period.
